EODData

MEMBERSHIP REGISTER LOG IN

FRA, 64Z: KEYMED BIOSCIENCES -0001

17 Nov 2025
LAST:

6.500

CHANGE:
 0.00		OPEN:
6.500		HIGH:
6.500		ASK:
0.000		VOLUME:
135
CHG(%):
0.00		PREV:
6.500		LOW:
6.500		BID:
0.000		 

CHART

RECENT END OF DAY PRICES

DateOpenHighLowCloseVolume
17 Nov 256.5006.5006.5006.500135
13 Nov 256.5006.5006.5006.500135
12 Nov 256.4006.4006.4006.400135
11 Nov 256.3006.3006.3006.300135
07 Nov 256.2506.2506.2506.250135
06 Nov 256.4006.4006.4006.400135
05 Nov 256.9506.9506.9506.950135
04 Nov 256.8506.8506.8506.850135
03 Nov 257.0507.0507.0507.050135
31 Oct 256.6006.6006.6006.600135

PROFILE

Name:KEYMED BIOSCIENCES -0001
About:Keymed Biosciences Inc., a biotechnology company, engages in the discovery and development of biological therapies in the autoimmune and oncology therapeutic areas in Mainland China and internationally. Its lead product candidate is CM310 for the treatment of moderate to severe atopic dermatitis (AD), chronic rhinosinusitis with nasal polyposis (CRSwNP), seasonal allergic rhinitis, prurigo nodularis, and respiratory related indications. The company is also developing CMG901, a Claudin 18.2 antibody drug conjugate in Phase III trial to treat gastric and solid tumors; CM326, a recombinant humanized monoclonal antibody in Phase II trial for the treatment of CRSwNP and asthma; CM313, a humanized monoclonal antibody that targets CD38 in Phase I/II clinical study to treat systemic lupus erythematosus, primary immune thrombocytopenia, and IgA nephropathy; and CM355, a CD20 x CD3 bispecific antibody in Phase I/II clinical trial for the treatment of lymphoma. In addition, it develops CM383, a humanized monoclonal antibody in Phase 1 trial to treat Alzheimer's Disease; CM512, which is in Phase I clinical study for the treatment of moderate-to-severe AD, asthma, and chronic obstructive pulmonary disease; CM336, a BCMA x CD3 bispecific antibody in Phase 1 trial to treat relapsed or refractory multiple myeloma (RRMM); CM350, a GPC3 x CD3 bispecific antibody in Phase 1 trial for the treatment of solid tumors; CM369, an anti-C-C motif chemokine receptor 8 monoclonal antibody in Phase 1 trial to treat tumors; CM518D1, an antibody drug conjugate in IND trial for the treatment of solid tumors; and CM380, a GPRC5D x CD3 bispecific antibody in IND trial to treat RRMM. The company has a license agreement with Belenos Biosciences, Inc.; Platina Medicines Ltd; Prolium Biosciences, Inc.; and Timberlyne Therapeutics, Inc. The company was formerly known as 2Health Biosciences, Inc. Keymed Biosciences Inc. was founded in 2016 and is headquartered in Chengdu, the People's Republic of China.
Sector:Healthcare
Industry:Biotechnology
Address:Building D2, Chengdu, China, 610219
Website:https://www.keymedbio.com
ISIN:KYG5252B1023

API SERVICE  NEW

Have you tried our new API Service yet?

For more information, visit our API page.

You can get your ApiKey over HERE.

If you're ready to get going, then jump over to:
https://api.eoddata.com

SYMBOL HISTORY

   Add to Watchlist

DOWNLOAD DATA

Download stock quote history quickly and easily in a variety of formats to suit your needs.

  Download

FUNDAMENTALS

Trailing P/E:-3.48 
Price to Sales:2.38 
Price to Book:0.65 
Profit Margin:-0.30 
Operating Margin:-0.27 
Return on Assets:-0.05 
Return on Equity:-0.09 
Revenue:106.28M 
Shares:294.6M 
Market Cap:1.915B 

TECHNICAL INDICATORS

MA5:6.391.7%
MA10:6.581.2%
MA20:6.540.5%
MA50:7.3312.8%
MA100:6.906.1%
MA200:5.7313.4%
STO9:31.25
STO14:47.62
RSI14:50.91
WPR14:-52.38
MTM14:0.25
ROC14:0.04 
ATR:0.20 
Week High:6.500.0%
Week Low:6.303.2%
Month High:7.058.5%
Month Low:6.0013.4%
Year High:8.4029.2%
Year Low:3.3395.3%